Syngen Biotech Co.,Ltd. (TPEX:8279)

Syngen Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	319.87	275.47	341.93	366.89	246.05	314.8
Cash & Short-Term Investments	319.87	275.47	341.93	366.89	246.05	314.8
Cash Growth	0.93%	-19.44%	-6.80%	49.11%	-21.84%	-25.65%
Accounts Receivable	373.34	462.13	422.56	387.8	472.06	388.16
Other Receivables	8.4	0.01	0	0	0	0
Receivables	381.75	462.14	422.56	387.8	472.06	388.16
Inventory	427.57	361.67	345.62	348.99	369.35	291.96
Prepaid Expenses	46	41.91	44.93	28.77	25.42	23.17
Total Current Assets	1,175	1,141	1,155	1,132	1,113	1,018
Property, Plant & Equipment	1,453	1,459	1,518	1,526	1,543	1,035
Long-Term Investments	322.92	333.08	324.34	331.74	313.75	293.55
Other Intangible Assets	37.22	37.87	27.57	24.13	22.96	23.42
Long-Term Deferred Tax Assets	13.26	16.89	18.86	17.44	16.21	12.32
Other Long-Term Assets	59.05	58.22	38.4	73.21	58.7	28.23
Total Assets	3,062	3,048	3,085	3,106	3,071	2,416

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	256.58	234.75	255.87	226.47	248.45	236.86
Accrued Expenses	58.26	83.56	78.84	72.8	79.89	64.72
Short-Term Debt	-	-	-	80	230	-
Current Portion of Long-Term Debt	-	59.03	59.03	59.03	-	-
Current Portion of Leases	15.84	15.17	14.71	13.38	14.85	13.7
Current Income Taxes Payable	39.73	33.55	35.18	62.06	76.99	58.39
Current Unearned Revenue	47.94	37.16	24.83	20.04	6.73	6.55
Other Current Liabilities	219.32	56.37	51.7	50.81	62.56	38.4
Total Current Liabilities	637.66	519.58	520.16	584.58	719.47	418.61
Long-Term Debt	-	4.92	163.95	222.97	182	50
Long-Term Leases	149.8	146.08	160.25	163.1	173.93	172.39
Long-Term Deferred Tax Liabilities	3.31	4.32	4.17	3.98	3.93	3.16
Total Liabilities	790.77	674.89	848.52	974.63	1,079	644.16

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	271.01	271.01	271.01	271.01	271.01	271.01
Additional Paid-In Capital	618.36	618.36	618.24	618.2	618.06	612.83
Retained Earnings	1,378	1,480	1,344	1,243	1,103	887.88
Comprehensive Income & Other	3.82	3.54	2.73	-0.26	-0.07	-0.36
Shareholders' Equity	2,271	2,373	2,236	2,132	1,992	1,771
Total Liabilities & Equity	3,062	3,048	3,085	3,106	3,071	2,416

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	165.63	225.19	397.93	538.49	600.78	236.08
Net Cash (Debt)	154.24	50.27	-56	-171.6	-354.73	78.72
Net Cash Growth	-	-	-	-	-	-54.53%
Net Cash Per Share	5.68	1.85	-2.06	-6.33	-13.07	2.90
Filing Date Shares Outstanding	27.1	27.1	27.1	27.1	27.1	27.1
Total Common Shares Outstanding	27.1	27.1	27.1	27.1	27.1	27.1
Working Capital	537.53	621.61	634.89	547.87	393.41	599.48
Book Value Per Share	83.81	87.57	82.51	78.66	73.49	65.36
Tangible Book Value	2,234	2,335	2,209	2,107	1,969	1,748
Tangible Book Value Per Share	82.44	86.17	81.49	77.76	72.64	64.50
Land	251	251	251	251	251	-
Buildings	822.72	820.48	729.7	717.09	702.28	532.98
Machinery	1,059	1,052	1,022	871.44	841.51	693.37
Construction In Progress	3.49	3.49	74.67	146.33	114.01	111.97

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 27, 2026

Data Sources Report a data error